Scisparc

Scisparc Interest Expense

The Interest Expense of Scisparc (SPRC) as of Oct 16, 2026 is -170,000.00 USD. In the previous year, Interest Expense was 954,000.00 USD — a change of -117.82% (lower).

Interest Expense

-170,000.00USD

YoY

-117.82%

Last updated:

Interest Expense of Scisparc is 2024 -170,000.00 USD. Interest Expense of Scisparc was 2023 954,000.00 USD. It decreases by -117.82% lower compared to the previous year.

The Scisparc Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2017
-490,000.00 USD
Jan 1, 2018
690,000.00 USD
Jan 1, 2019
-260,000.00 USD
Jan 1, 2020
590,000.00 USD
Jan 1, 2021
-20,000.00 USD
Jan 1, 2022
6.91 M USD
Jan 1, 2023
954,000.00 USD
Jan 1, 2024
-170,000.00 USD
The Scisparc Interest Expense history
YEARInterest ExpenseYoY
-170,000.00USD-117.82%
954,000.00USD-86.19%
6.91 MUSD-34,650.00%
-20,000.00USD-103.39%
590,000.00USD-326.92%
-260,000.00USD-137.68%
690,000.00USD-240.82%
-490,000.00USD—
0.00USD-100.00%
-40,000.00USD-500.00%
10,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? Scisparc Ltd., listed under the ticker SPRC with ISIN IL0010951403, is a biotechnology company headquartered in Tel Aviv-Yafo, Israel. The company operates in the healthcare sector and has a workforce of three employees. Scisparc Ltd. went public through an IPO on December 22, 2021. Its website is https://scisparc.com/. The company is engaged in the development of pharmaceutical products based on cannabinoid technologies, focusing on repurposing dronabinol for various medical conditions. Specific drug development programs include THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain treatment. Scisparc Ltd. is a clinical stage pharmaceutical company, indicating its focus on advancing drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's activities are centered around leveraging cannabinoid-based approaches to address unmet medical needs in multiple therapeutic areas. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Interest Expense of Scisparc is -170,000.00 USD in 2024.

Interest Expense of Scisparc changed from 954,000.00 USD to -170,000.00 USD, representing a -117.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Scisparc since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Scisparc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Scisparc

All Key Metrics — Scisparc